openPR Logo
Press release

Deep Research: Current and Future Trends in Rx-to-OTC Switching with Insight from Key Industry Opinion Leaders

02-08-2019 07:59 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Rx-to-OTC Switching

Rx-to-OTC Switching

Rx-to-OTC Switching

Researchmoz added Most up-to-date research on "Current and Future Trends in Rx-to-OTC Switching with Insight from Key Industry Opinion Leaders" to its huge collection of research reports. An insight on the important factors and trends influencing the market.

Rx-to-OTC switching is the process in which a drug which has formerly been marketed as a prescription-only Rx drug is authorized for sale to the general public, without the need for a prescription. For patients and healthcare providers, OTC products can reduce the cost of medical treatment and allow easier access of drugs to patients, and for pharmaceutical companies, they allow lifecycle extension of an off-patent drug by transferring it to the consumer environment, and facilitate renewed revenue growth.

Based on overall revenue, the OTC pharmaceutical market has been dominated by four main categories: cough, cold, and allergy; analgesics; dermatologicals; and gastrointestinals. These categories have led the OTC drugs market over the last two decades in revenue and volume.

Get a Sample PDF at: https://www.researchmoz.us/enquiry.php?type=S&repid=1381819

GBI Research conducted a targeted industry survey of experts and key opinion leaders (KOL) in the field of Rx-to-OTC switching to gather insight and opinions on the trends and commercial prospects of switching pharmaceuticals. The majority of these respondents believe that there will be an increase in Rx-to-OTC switching in the next five years, particularly in the weight control, dermatological and cough, cold and allergy segments.

Key barriers to switching include the potential for misuse and abuse of drugs, particularly for analgesics, and the resultant need to demonstrate safety and clear labelling to regulatory agencies. A lack of harmonization in OTC approval processes between different countries also increases the burden for companies that want to launch their products across multiple territories.

Scope

- What are the characteristics of an ideal Rx-to-OTC switching candidate?
- How well have recent Rx-to-OTC switches performed, and into which therapeutic categories do they fall?
- What are the key drivers and barriers of the global OTC market?
- What are the key future trends that will influence the OTC market and Rx-to-OTC switches worldwide?
- Which disease areas do industry professionals believe to hold the most opportunity for switches?
- Which geographies hold the most potential for an OTC product, and which are the most amenable to Rx-to-OTC switching?

Reasons to buy

- Gain a thorough understanding of Rx-to-OTC switching, including key concepts, the regulatory environment and geographic variations.
- Understand the competitive environment of key disease areas in the OTC product space.
- Identify the drug classes and indications which pharmaceutical professionals around the world believe hold the most opportunity for Rx-to-OTC switching.
- Understand in depth the key trends driving and holding back the OTC market, both globally and within specific geographies.
- Identify the geographies that are poised for growth, and those at the highest risk of experiencing reverse switching of products from OTC-to-Rx.
- Understand which companies have been the most active in pursuing mergers and acquisitions in the OTC space.

Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/current-and-future-trends-in-rxtootc-switching-with-insight-from-key-industry-opinion-leaders-report.html/toc

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

ResearchMoz
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Email: sales@researchmoz.us
Website @ https://www.researchmoz.us/
Tel: 866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-621-2074
For More Reports Visit @ http://marketresearchlatestreports.blogspot.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Deep Research: Current and Future Trends in Rx-to-OTC Switching with Insight from Key Industry Opinion Leaders here

News-ID: 1571434 • Views:

More Releases from Rx-to-OTC Switching

Rx-to-OTC Switching with Insight from Key Industry Opinion Leaders : Market Trends, Analysis, Growth and Status 2017
Rx-to-OTC Switching with Insight from Key Industry Opinion Leaders : Market Tren …
Albany, NY, 28th November : Recent research and the current scenario as well as future market potential of "Current and Future Trends in Rx-to-OTC Switching with Insight from Key Industry Opinion Leaders" globally. Rx-to-OTC switching is the process in which a drug which has formerly been marketed as a prescription-only Rx drug is authorized for sale to the general public, without the need for a prescription. Get PDF for more Professional and

More Releases for OTC

Lawsuit filed for Investors who lost money with shares of adidas AG (OTC: ADDYY, …
An investor, who purchased shares of adidas AG (OTC: ADDYY, OTC: ADDDF), filed a lawsuit over alleged violations of Federal Securities Laws by adidas AG in connection with certain allegedly false and misleading statements. Investors who purchased shares of adidas AG (OTC: ADDYY, OTC: ADDDF) have certain options and for certain investors are short and strict deadlines running. Deadline: June 27, 2023. adidas AG (OTC: ADDYY, OTC: ADDDF) investors should contact
Investigation for Investors in adidas AG (OTC: ADDYY, OTC: ADDDF) announced over …
An investigation on behalf of investors in shares of adidas AG (OTC: ADDYY, OTC: ADDDF) was announced over potential breaches of fiduciary duties by certain officers and directors at adidas AG. Investors who purchased shares of adidas AG (OTC: ADDYY, OTC: ADDDF) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain adidas AG officers and
AMERICAN HEMP VENTURES INC (OTC: AMHV) TO BECOME YOUNEEQAI TECHNICAL SERVICES In …
FOR IMMEDIATE RELEASE Denver Colorado, March 31, 2023, American Hemp Ventures, Inc. (OTC: AMHV) announced today that its name has changed effective immediately to YouneeqAI Technical Services inc. (OTC: YQAI) reflecting the Company's new focus into cookie-less AI technology services. The current management team has over 50 years of experience in technology services and innovation. Murray Galbraith, YQAI's CEO, is the Founder of YouneeqAI's software solution and has operated several private technology
Investigation announced for Investors who lost money with shares of adidas AG (O …
An investigation was announced for investors of adidas AG (OTC: ADDYY, OTC: ADDDF) shares over potential securities laws violations by adidas AG. Investors who purchased shares of adidas AG (OTC: ADDYY, OTC: ADDDF), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of adidas AG (OTC: ADDYY,
Fuel Cell Market Technological Trends and Business Opportunities 2021 To 2026; P …
MarketInsightsReports has published a report titled global Fuel Cell Market research report 2021 that is a detailed observation of several aspects, including the rate of growth, technological advances, and different methodologies implemented by the primary current market players. The report is based on a collective analysis of data, which is obtained through primary and secondary research. It provides a systematic approach to the current and prospective scenario of this market. The
Deadline on Nov. 9th upcoming in Lawsuit for Investors in Harborside Inc. (OTC: …
The Shareholders Foundation announced that a deadline is coming up on November 9, 2020 in the lawsuit filed for certain investors of Harborside Inc. (OTC: HSDEF, OTC: HBORF). Investors who purchased shares of Harborside Inc. (OTC: HSDEF, OTC: HBORF) have certain options and there are strict and short deadlines running. Deadline: November 9, 2020. Harborside Inc. stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. According to